ADVERTISEMENT

Krsnaa Diagnostics IPO - Premium Valuation For Differentiated Diagnostics: Dolat Capital

Krsnaa Diagnostics IPO - Premium Valuation For Differentiated Diagnostics: Dolat Capital

<div class="paragraphs"><p>A scientist places vials in a centrifuge during diagnostic activity. (Photographer: Akos Stiller/Bloomberg)</p></div>
A scientist places vials in a centrifuge during diagnostic activity. (Photographer: Akos Stiller/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital's IPO Report

Krsnaa Diagnostics Ltd., is a diagnostic service provider with business spread across radiology, pathology and public private partnership (PPP) to public and private hospitals, medical colleges and community health centers across India.

Krsnaa Diagnostics has 1,823 diagnostic centres spread across 13 states (primarily non-metro and lower-tier cities and towns).

Of this 1,797 centers are pursuant to PPP agreements, has a track record of winning ~78% of all tenders since inception.

Proceeds from listing will be used for establishing diagnostic centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra apart from debt repayment.

Click on the attachment to read the full IPO report:

Dolat Capital Krsnaa Diagnostics IPO Note.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.